Treating Melanoma After Immunotherapy and Targeted Therapies
April 17th 2017Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses options for treating melanoma after the use of targeted therapies and immunotherapy.
Watch
Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer
April 12th 2017Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.
Watch
Ideal Treatment for Melanoma in the Adjuvant Setting
April 11th 2017Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.
Watch
Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck Cancer
April 10th 2017Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Watch
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AML
April 6th 2017Sudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Watch
Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma
April 6th 2017Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.
Watch
Testing Positive Messaging in Smoking Cessation Counseling for Lung Cancer
April 5th 2017Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses an ongoing trial at Yale Cancer Center exploring the use of positive messaging in smoking cessation counseling for lung cancer during the AACR Annual Meeting.
Watch